Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
Frederick Wayne A.I. reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Frederick Wayne A.I. received an equity grant of 1,660 shares of common stock on a grant/award basis, with no cash paid per share. These are restricted stock units that vest in full on April 30, 2027. After the award, he holds 3,818 shares directly. Settlement of the vested RSUs is deferred under Insulet’s non-employee director deferred compensation plan until after his board service ends.
BORIO LUCIANA reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Luciana Borio received an equity grant of 1,660 shares of common stock in the form of restricted stock units. The RSUs are an annual equity award that will be settled on a one-for-one basis in common stock. They vest in full on April 30, 2027, aligning her compensation with long-term shareholder interests. Following this award, she holds a total of 4,747 shares of Insulet common stock directly.
Insulet Corporation reported governance updates and voting results from its 2026 annual stockholder meeting. The Board approved amended and restated Bylaws that designate the Delaware Court of Chancery, or other Delaware courts as needed, as the exclusive forum for certain corporate disputes, and federal district courts as the exclusive forum for claims under the U.S. Securities Act of 1933.
At the meeting, 61,782,973 of 69,263,714 shares entitled to vote were represented, forming an 89.19% quorum. Stockholders elected three Class I directors for three-year terms, approved the advisory vote on executive compensation, and ratified PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.
Insulet Corp President and CEO Ashley McEvoy reported a routine tax-related share disposition and updated holdings. A total of 1,411 shares of common stock were withheld on May 13, 2026 at $148.84 per share to cover tax obligations tied to vesting restricted stock units, according to the footnote. After this withholding, McEvoy directly owns 22,551 common shares and indirectly holds 4 additional shares through a trust.
Insulet Corp. passive investor Capital Research Global Investors amended its Schedule 13G to report beneficial ownership of 1,669,556 shares of Common Stock, equal to 2.4% of 70,395,848 shares outstanding as of 03/31/2026. The filing shows sole voting power of 1,664,274 and sole dispositive power of 1,669,556.
Insulet Corporation reported strong Q1 2026 results, with revenue of $761.7 million, up 33.9% from a year earlier, driven by 36.9% growth in Omnipod products and especially rapid international expansion.
Net income rose to $91.1 million and diluted EPS to $1.30, helped by higher volumes and pricing, partly offset by a lower gross margin of 69.5% due to increased inventory reserves and warranty costs from a voluntary Omnipod 5 medical device correction.
Operating cash flow was $113.8 million and free cash flow $89.5 million. Insulet ended the quarter with $480.4 million in cash and $948.1 million of net debt, and repurchased $300 million of stock under accelerated share repurchase agreements while extending and expanding its buyback authorization.
FMR LLC reported beneficial ownership of 3,963,512.09 shares of Insulet Corp common stock (CUSIP 45784P101), representing 5.6% of the class as of 03/31/2026. The cover data shows sole voting power of 3,727,171.97 and sole dispositive power of 3,963,512.09. The filing names Abigail P. Johnson as having dispositive power for the same share total and references a Power of Attorney and Exhibit 99 for related subsidiary and agreement information.
Insulet Corporation reported strong first quarter 2026 results with higher guidance for the year. Revenue reached $761.7 million, up 33.9% (or 30.1% in constant currency) and above the high end of its prior growth range. Omnipod revenue was $758.4 million, rising 36.9%, including $515.6 million from U.S. Omnipod, up 28.3%, and $242.9 million internationally, up 59.4%.
Operating income was $122.1 million, or 16.0% of revenue, while net income increased to $91.1 million, or $1.30 per diluted share, compared with $35.4 million and $0.50 a year earlier. Free cash flow was $89.5 million. The company repurchased 1.25 million shares and now expects full-year 2026 total revenue growth of 21%–23% in constant currency and adjusted EPS growth of more than 25%.
Insulet Corp Schedule 13G: Vanguard Capital Management reports beneficial ownership of 5,277,842 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing lists 698,568 shares with sole voting power and 5,277,842 shares with sole dispositive power.
The filing is signed by Ashley Grim as Head of Global Fund Administration on 04/30/2026.
Insulet Corporation furnished an update and clarification related to its voluntary Medical Device Correction. The Company previously reported 18 Serious Adverse Events and later expanded communications on April 10, 2026 to include 13 expired lots, stating this does not change its earlier estimated financial impact. The updated communication referenced 29 confirmed Serious Adverse Events. The Company also explained that an FDA website statement citing 476 serious injuries actually refers to 476 Medical Device Reports potentially related to the correction, rather than 29 confirmed Serious Adverse Events. The information is furnished under Item 7.01 and is not deemed filed under the Exchange Act.